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The extent to which neurotrophic factors are able to
not only rescue the auditory nerve from deafferenta-
tion-induced degeneration but also promote process
regrowth is of basic and clinical interest, as regrowth
may enhance the therapeutic efficacy of cochlear pros-
theses. The use of neurotrophic factors is also relevant
to interventions to promote regrowth and repair at other
sites of nerve trauma. Therefore, auditory nerve survival
and peripheral process regrowth were assessed in the
guinea pig cochlea following chronic infusion of BDNF
1 FGF1 into scala tympani, with treatment initiated 4
days, 3 weeks, or 6 weeks after deafferentation from
deafening. Survival of auditory nerve somata (spiral
ganglion neurons) was assessed from midmodiolar sec-
tions. Peripheral process regrowth was assessed using
pan-Trk immunostaining to selectively label afferent
fibers. Significantly enhanced survival was seen in each
of the treatment groups compared to controls receiving
artificial perilymph. A large increase in peripheral proc-
esses was found with BDNF 1 FGF1 treatment after a
3-week delay compared to the artificial perilymph con-
trols and a smaller enhancement after a 6-week delay.
Neurotrophic factor treatment therefore has the poten-
tial to improve the benefits of cochlear implants by
maintaining a larger excitable population of neurons
and inducing neural regrowth. VC 2007 Wiley-Liss, Inc.
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In vivo neural deafferentation can result in cell
death from neurotrophin deprivation (see Mattson and
Scheff, 1994; Mattson, 1998). Withdrawal of neurotro-
phic factors (NTFs) leads to reactive oxygen species
(ROS) production, and, ultimately, to cell death (for a
review, see Kirkland and Franklin, 2003). These mecha-
nisms contribute to neurodegeneration in Alzheimer’s
disease (de la Monte et al., 2000; Gilgun-Sherki et al.,
2003; Chong et al., 2004; Summers, 2004), Parkinson’s
disease (Le and Frim, 2002; Tenenbaum et al., 2002;
Thomas and Le, 2004), and traumatic brain injury
(Lewen et al., 2000). NTF deprivation may also contrib-
ute to degeneration of the auditory nerve (AN) and loss
of its somata (spiral ganglion cells, SGCs) after the onset
of deafness, when sensory cells in the organ of Corti are
damaged and lost. Studies have now shown that such
degeneration can be reduced in mature cochlea if NTFs
are provided to the spiral ganglion neurons (SGN) in
vivo (Schindler et al., 1995; Ernfors et al., 1996;
Staecker et al., 1996b; Miller et al., 1997; Ylikoski et al.,
1998; Shoji et al., 2000; Lalwani et al., 2002; Shinohara
et al., 2002; Gillespie et al., 2004; Nakaizumi et al.,
2004; Yamagata et al., 2004).
The clinical consequence of AN degeneration is
hearing loss. The cochlear neuroprosthesis restores hear-
ing by bypassing the damaged sensory epithelium and
presenting encoded electrical signals directly to the AN.
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The benefits, including speech perception without lip-
reading (Skinner et al., 1994, 1997; Waltzman et al.,
1997; Firszt et al., 2004), depend on the density and
excitability of the surviving AN (Clopton et al., 1980;
Nadol et al., 1989; Incesulu and Nadol, 1998; also see
Skinner et al., 2002) and electrode location. Interven-
tions that deliver NTFs prevent AN degeneration and
maintain SGC electrical excitability (Shinohara et al.,
2002; Yamagata et al., 2004). Application of neural
growth factor has been shown to be effective in enhanc-
ing AN survival following sensory cell loss after delays of
2 weeks (Shah et al., 1995; Gillespie et al., 2004) or
even 6 weeks (Yamagata et al., 2004).
There is also benefit to survival or regrowth of AN
peripheral processes. With closer proximity to AN fibers,
stimulation threshold of cochlear prostheses can be
reduced (also reducing electronic power requirement)
and neural response dynamic range is enhanced. We
therefore explored of the use of BDNF þ FGF1 to both
enhance AN survival and induce peripheral process
regrowth in vivo. BDNF has consistently been shown to
promote AN survival after deafferentation (e.g., Lefebvre
et al., 1994; Hartnick et al., 1996; Malgrange et al.,
1996; Staecker et al., 1996a, 1996b; Gabaizadeh et al.,
1997; Miller et al., 1997; Mou et al., 1997; Gillespie
et al., 2001; Nakaizumi et al., 2004). Acidic fibroblast
growth factor (FGF1) plays an important role in neurite
outgrowth in the immature auditory system (Dazert
et al., 1998; Hossain and Morest, 2000) during develop-
ment. Both BDNF and FGF1 can induce neurite out-
growth from SGN in vitro (Hartnick et al., 1996;
Malgrange et al., 1996; Dazert et al., 1998; Hossain and
Morest 2000; Gillespie et al., 2001; Aletsee et al., 2003),
and Altschuler et al. (1999) reported previously that
although BDNF alone induced process regrowth, the
richest and most extended labeling into the region of the
previous organ of Corti was observed in cochlea treated
with both BDNF and FGF1. FGF1 alone was less effec-
tive, with fewer processes and less growth into the organ
of Corti region. The increased effectiveness of the com-
bination of BDNF and FGF1 was explained via BDNF
functioning both as a survival factor and to induce
regrowth, with FGF1 further influencing regrowth. The
current data set extends the work of Altschuler et al.
(1999) by precisely defining the timing within which the
combination of BDNF and FGF1 is clinically useful. We
examined the efficacy of BDNF þ FGF1 to promote
SGC survival and regrowth of the AN peripheral proc-
esses, with application beginning 4 days, 3 weeks, or 6
weeks following sensory cell loss.
MATERIALS AND METHODS
Subjects
Pigmented male and female guinea pigs (250–300 g, n¼ 40;
obtained from Elm Hill Breeding Laboratories, Chelmsford,
MA) were used in this study. Normative histological data
from an additional 8 animals, purchased from the same sup-
plier and euthanized within an equivalent age/weight range,
were drawn from an existing laboratory database (unpublished
observations). The experimental protocol was reviewed and
approved by the Animal Care and Use Committee at the
University of Michigan. All procedures conformed to the
National Institutes of Health Guidelines for the Care and Use
of Laboratory Animals.
Experimental Design
Subjects were divided into six groups (n  6 animals
per group) split across two treatment conditions and three
time points. Subjects in these groups were deafened via sys-
temic aminoglycoside and diuretic treatment. A shift in
threshold sensitivity, measured using the sound-evoked audi-
tory brainstem response (ABR), of at least 60 decibels sound
pressure level (dB SPL) post–aminoglycoside/diuretic treat-
ment was required for each subject to be included in the
study. Treatment conditions for deafened animals included ex-
perimental NTF groups treated with a combination of BDNF
(100 lg/mL) and FGF1 (50 ng/mL) diluted in a modified
Konishi’s solution (Konishi and Kelsey, 1973) hereafter termed
artificial perilymph (AP; 118 mM NaCl, 30 mM KCl, 2.0
mM MgSO4, 1.2 mM CaCl2, 5.0 mM HEPES; pH ¼ 7.40,
osmolality ¼ 285–294 mOsm) with 0.1% guinea pig serum
albumin; control groups were treated with AP with 0.1%
guinea pig serum albumin. All substances were chronically
delivered into the scala tympani via an intracochlear cannula
and osmotic minipump (0.5 lL/hr for 26 days). Treatment
(AP or NTFs) was initiated 4 days, 3 weeks, or 6 weeks after
deafening. Subjects were sacrificed and then assessed histologi-
cally following the 26-day treatment. Thus, two groups were
sacrificed 30 days after deafening, two groups were sacrificed
47 days after deafening, and the last two groups were sacri-
ficed 68 days after deafening.
Auditory Physiology
Normal hearing at the onset of the investigation was
verified using sound-evoked ABR; threshold deficits (of at
least 60 dB) were verified 4–7 days postdeafening. Prior to
the ABR procedures, animals were anesthetized with keta-
mine (40 mg/kg intramuscularly) and xylazine (10 mg/kg
intramuscularly) and placed on a warm heating pad, and their
ear canals were inspected using an operating microscope to
assure they were free of wax and that there was no inflamma-
tion of the tympanic membrane or effusion of the middle ear.
Needle electrodes were then inserted subcutaneously at the
nose, at the vertex, and in the thigh. ABR thresholds were
measured using brief (160-lsec, 50/sec) alternating phase
clicks. Tucker-Davis-Technology (TDT; Alachua, FL) soft-
ware was used for signal generation (SigGen 3.2). Signals were
presented using TDT System II/System III hardware, and a
200-Ohm transducer (Beyer Dynamic, Farmingdale, NY) was
coupled to the external auditory meatus through a tube con-
nected to the transducer (Beyer DT-48; Beyer Dynamic,
Farmingdale, NY). Sound levels were initially set at 80 dB
SPL for baseline tests and 120 dB SPL for tests conducted
postdeafening. Signal calibration was based on the maximum
peak–peak value of the click waveform, assuming an SPL
equivalent to a continuous sinusoid with the same peak–peak
1960 Miller et al.
Journal of Neuroscience Research DOI 10.1002/jnr
value. Waveforms were measured using a storage oscilloscope
and the SPL computed from the microphone sensitivity value.
Sound intensity was decreased in 10–20 steps initially, with 5-
dB decrements used to determine threshold. Responses to
1,024 presentations were averaged for each click/level combi-
nation using a Tucker-Davis data acquisition system (BioSig
3.2). Threshold was defined as the lowest signal level at which
a response could be reliably elicited based on ABR wave III
or ABR wave IV. ABR wave III is the most robust compo-
nent of the guinea pig ABR waveform and the most resistant
to excitotoxic trauma (Puel et al, 1995; Le Prell et al., 2004).
Deafening
Pathology of sensory receptor cells can be induced by
aminoglycoside antibiotics (Webster and Webster, 1981;
Nadol et al., 1989; McFadden et al., 2004) or noise
(Spoendlin, 1971; Spoendlin and Brun, 1973; Rask-Andersen
et al., 2000). In these experiments, deafening was accom-
plished by treatment with a combination of a systemic amino-
glycoside antibiotic (kanamycin) and a diuretic (ethacrynic
acid). Spiral ganglion cell death begins after hair cell death;
West et al. (1973) clearly demonstrated significant SGC
degeneration as early as 2 weeks after kanamycin/ethacrynic
acid treatment, with a much greater decrease in SGC survival
by 8 weeks and then a marginal decrease continuing from 8
to 32 weeks postdeafening. Our more recent studies (Jyung
et al., 1989) revealed little change in SGC density 2 weeks after
kanamycin/ethacrynic acid treatment, with a rapid and signifi-
cant decrease observed by 4 weeks and continuing to at least
16 weeks post–kanamycin/ethacrynic acid treatment. Presum-
ably, the degeneration of peripheral processes began after the
2-week assessment and prior to the 4-week assessment. Taken
together, in the 4-day postdeafened group, treatment begins
in a relatively normal spiral ganglion. In contrast, in the 3-
week postdeafened group, treatment begins in a cell popula-
tion in which degeneration has clearly begun, and in the
6-week postdeafened group, it begins in a cell population in
which degeneration is extensive (>40% loss).
In this investigation, all subjects were deafened with
subcutaneous kanamycin (450 mg/kg) followed 2 hr later by
intravenous ethacrynic acid (60 mg/kg) as in West et al.
(1973). For intravenous. injection into the jugular vein,
guinea pigs were anesthetized (40 mg/kg ketamine intramusc-
ularly, 10 mg/kg xylazine intramuscularly) and placed on a
warm heating pad. The jugular vein was surgically exposed
and cannulated, and ethacrynic acid (10 mg/mL) was slowly
injected over 1–2 min. In the guinea pig, this treatment regi-
men resulted in loss of both inner and outer hair cells (sensory
cells), except for a few scattered inner hair cells remaining in
the fourth turn (Izumikawa et al., 2005). The efficacy of the
deafening was initially assessed by ABR (60 dB threshold shift
necessary for initial study inclusion) and subsequently con-
firmed by assessment of hair cell loss in plastic-embedded mid-
modiolar sections. After this procedure only scattered outer
and inner hair cells remained and only in the most apical turn.
Sections through every cochlea were checked for inner hair
cell survival, and any subject showing more than a few inner
hair cells surviving in the apical turn was excluded from the
study. There were three animals excluded because of remain-
ing hair cells remaining.
Microcannulation of the Cochlea
The surgical procedures used in this investigation have
been described in detail previously (Brown et al., 1993; Prieskorn
and Miller, 2000). In brief, guinea pigs were anesthetized
(40 mg/kg ketamine administered intramuscularly, 10 mg/kg
xylazine administered intramuscularly, 1% lidocaine delivered
subcutaneously for local analgesia) and placed on a warm heat-
ing pad, and the dorsal bulla was exposed using aseptic tech-
nique. After exposing the middle ear, a cochleostomy was
performed to access basal-turn scala tympani. A microcannula
constructed of vinyl (size V/4; SCI Commodities, Lake
Havasu, AZ) and polyimide (outer diameter ¼ 0.16 mm,
Microlumen, Tampa, FL) tubing was then inserted and
secured to the bulla and the dorsal skull. A ball of silastic
0.5 mm distal to the end of the cannula was seated against the
outer wall of the cochlea to prevent overinsertion of the can-
nula as well as to seal the cochleostomy and prevent fluid
leaking out of the cochlea. The bulla defect was sealed with
carboxylate cement (Durelon, 3M ESPE AG, Germany), and
the cannula was cemented to the dorsal skull using methyl
methacrylate (Lang Dental Mfg. Co., Wheeling, IL). An os-
motic minipump (Alzet model 2002; Durect Corporation,
Cupertino, CA), filled with NTFs or AP, was primed in a
378C–388C water bath to allow for immediate intracochlear
fluid delivery, then connected to the rostral termination of the
cannula and inserted into a subcutaneous pocket between the
scapulae. Cannulas were similarly filled with NTFs or AP
prior to implantation. All osmotic minipumps dispensed fluids
at a rate of 0.5 lL/hr for 14 days. To prevent a disruption in
intracochlear fluid delivery, pumps were surgically removed
on day 13 and replaced with new pumps such that treatment
was continuous throughout the 26-day interval.
Histological Examination
Subjects were deeply anesthetized with sodium pento-
barbital (FatalPlus; Vortech Pharmaceuticals, Dearborn, MI)
and perfused intracardially with 0.1M phosphate buffer (pH ¼
7.40) followed by 4% paraformaldehyde. After decapitation,
the temporal bones were removed and opened to expose the
cochleas. The cochleas were dissected open and gently flushed
with fixative, followed by postfixation with 4% paraformalde-
hyde for 2 hr. The otic capsule, lateral wall, and Reissner’s
and tectorial membranes were removed, and the cochlear
spiral was placed in 0.3% hydrogen peroxide to remove en-
dogenous peroxidase activity. Following several rinses in PBS,
the tissues from all deafened animals were placed in phos-
phate-buffered saline (PBS) plus 0.1% Triton-X (Electron
Microscopy Sciences, Ft. Washington, PA) and 3% normal
goat serum (Vector Laboratories, Burlingame, CA) for 1 hr.
The primary antibody was the pan-Trk antibody c-Trk
(Ab-1; Oncogene Research Products, Boston, MA); it was
diluted 1:100, and tissues were placed in this solution for 20–
24 hr at 48C. Detection of the primary antibody was accom-
plished using an avidin-biotinylated horseradish peroxidase
macromolecular complex (Avidin-Biotin Complex, Vectastain
Delayed Treatment Rescues Neurons 1961
Journal of Neuroscience Research DOI 10.1002/jnr
Elite ABC kit; Vector Laboratories, Burlingame, CA). Visual-
ization of the antibody was done with 0.05% 3,30-diamino-
benzadine (DAB peroxidase substrate kit, Vector Laboratories,
Burlingame, CA).
Tissues (including those from deafened animals and
those from untreated control animals with intact hearing proc-
essed as part of the normative database) were decalcified and
embedded in JB-4 Resin (a water soluble embedding medium
based on glycol methacrylate plastic embedding; Electron
Microscopy Sciences, Ft. Washington, PA). Midmodiolar plas-
tic sections were cut 3–4 lm thick; every third midmodiolar
section was mounted on a glass slide until 15 sections had
been mounted. These sections were then stained with tolui-
dine blue (1.46 g; J. T. Baker, Phillipsburg, NY) and basic
fuchsin (0.54 g; Allied Chemical, New York, NY), dissolved
in 30% ethanol (200 mL; PharmCo Products Inc., Brookfield,
CT), and saved for SGC counts and density measures. Six
additional consecutive midmodiolar sections were cut from
immunolabeled cochleas and mounted on glass slides without
the toluidine blue/basic fuchsin stain. These tissues were used
for assessment of regrowth of peripheral processes based on
pan-Trk labeling.
In a small number of additional animals (n ¼ 3), tissues
were not sectioned with a cryostat but were instead prepared
as surface dissections. Coimmunofluorescent labeling for pan-
Trk and the efferent-specific marker synaptophysin (IGN
Pharmaceuticals, Inc.) was performed using highly specific sec-
ond antibodies (Molecular Probes) with different Alexa chro-
mophores to show the specificity of the labeling. Merged
images were acquired with an Olympus FV-500 laser scanning
focal microscope.
Pan-Trk Antibody Selection
Pan-Trk antibodies immunostain all members of the
Trk receptor family (TrkA, TrkB, TrkC) as well as Trk pro-
tein inside prostrate epithelial cell bodies (Pflug et al., 1995).
Antibodies to pan-Trk have been used to identify the cyto-
plasmic domain of Trk receptors on SGC explants (Mou
et al., 1997) and also to label the AN peripheral processes
(Altschuler et al., 1999). The antibody we selected [C-Trk
(Ab-1)] is a polyclonal antibody raised against a peptide
sequence (A L A N A P P V Y L D V L G) found in the C-
terminal domain corresponding to residues 777–790 (Onco-
gene Research Products, catalog PC31).
Pan-Trk-Positive Fiber Quantification of AN
Peripheral Processes
Pan-Trk immunostaining was evaluated in tissues from
all deafened animal groups using a 1003 objective. Six
staining profiles were examined on six sections from each
animal. Positively stained fibers were counted only if they
emerged from the habenula perforata, indicating afferent
fibers that had been maintained in or had regrown into the
region of the basilar membrane/organ of Corti. Fiber length
could not be determined; thus, quantification was limited to
fiber number.
Cell Density of Spiral Ganglion Cells
Every third midmodiolar section was mounted on a glass
slide until 15 sections had been mounted and a random start
point generated; the six sections from that point were used to
generate an ‘‘analysis length’’ of 72 lm. Six Rosenthal’s canal
profiles, visible on each section (two from the basal cochlea,
two from the middle turn, and two from the apical turn),
were assessed for each toluidine blue/basic fuchsin–stained
section by an observer blind to treatment condition. Spiral
ganglion cells were counted as normal if they met these crite-
ria: (1) had a diameter of 14–22 lm and an area of 153–380
lm2; and (2) had a nucleus, with a diameter of 5–10 lm. The
outline of each profile of Rosenthal’s canal was traced using a
computer mouse. Cell count and cell area were then used to
calculate cell density. All measurements were calculated using
the Metamorph Image Acquisition, Enhancement, and Analy-
sis System (Molecular Devices Corporation, Sunnyvale, CA).
Statistical Comparisons
Spiral ganglion cell density was evaluated for each of the
six cochlear-turn profiles in the midmodiolar sections from the
animals tested in this investigation; these values were compared
to normative data from animals that were not deafened or oth-
erwise treated (n ¼ 8, unpublished observations, laboratory nor-
mative data). Initial statistical comparisons of SGC density were
for untreated animals and used one-way analysis of variance
(ANOVA) based on profile number (1–6) to confirm that SGC
density did not vary with profile number (i.e., cochlear place) in
normal (untreated) ears. Two-way ANOVA with treatment and
profile number (1–6) as factors was used for subsequent compar-
isons performed at each treatment delay (4 days, 3 weeks, and 6
weeks). There was no main effect for profile or interaction
effects for profile (i.e., SGC density did not vary with profile
number, and the statistical reliability of changes in SGC density
and fiber count associated with NTF treatment did not depend
on which profile was evaluated, all P > 0.1). As there was no
effect of profile (cochlear place), data were collapsed across pro-
files and additional statistical comparisons were based on data
from the whole cochlea without regard to profile number.
Two-way ANOVA with treatment (AP, NTFs) and
treatment delay (4 days, 3 weeks, and 6 weeks) as factors was
used to determine the statistical reliability of protection
induced by NTF treatment in deafened animal groups. To
balance the data sets for SGC density comparisons including
normal untreated ears, two procedures were used. First, one-
way ANOVA was employed to compare untreated (AP) con-
trols with (NTF) treated groups after 4-day, 3-week, and 6-
week delays in the AP and in the NTF groups. Second, we
arbitrarily assigned time points of 4 days, 3 weeks, or 6 weeks
to the baseline data such that two-way ANOVA using time
point (4 days, 3 weeks, and 6 weeks) and treatment (none,
AP, NTFs) was possible. The data handling procedures
yielded the same pattern of results, that is, statistically reliable
differences revealed with the one-way ANOVA were also
revealed using the two-way ANOVA, and vice versa. Statisti-
cal comparisons of the number of pan-Trk-positive fibers
included an initial two-way ANOVA with treatment and pro-
file number (1–6) as factors, with comparisons conducted at
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each treatment delay (4 days, 3 weeks, and 6 weeks). There
was no main effect for profile, and as above, data were col-
lapsed across profiles, and additional statistical comparisons
[two-way ANOVA with treatment (AP, NTFs) and treatment
delay (4 days, 3 weeks, and 6 weeks) as factors] were based on
data from the whole cochlea without regard to profile num-
ber. This analysis allowed the efficacy of the NTF treatment
to be compared to AP control–treated material at each of the
three postdeafening survival periods and also the influence of
the percentage of surviving SGCs at the initiation of treatment
on treatment efficacy to be assessed.
Normal untreated ears immunolabeled using antibodies
to pan-Trk were evaluated as surface preparations; thus, there
was no quantification or statistical comparison of normal and
deafened ears on this measure. SigmaStat for Windows (ver-
sion 2.03, SPSS., Inc., Chicago, IL) was used for all analyses.
Fig. 1. A: Pan-Trk immunoperoxidase antibody labels afferent proc-
esses and synaptic terminals at the bases of inner hair cells in surface
preparations of normal guinea pig cochlea. Tissue from the second
turn of the cochlea is shown. B: Confocal analysis of coimmuno-
fluorescent labeling for pan-Trk and the efferent-specific antisynapto-
physin antibody shows pan-Trk labeling of afferents (green) is distinct
from synaptophysin labeling of efferents (red). The small portion of
‘‘yellowish’’ label from the overlap of the red and green labels may
indicate the regions where efferent neurons make synaptic contact
with afferent neurons.
Fig. 2. Significant scar formation was evident in the region that nor-
mally has hair cells (see asterisks, A and B) in deafened control animals
(A: 4 days deaf, then artificial perilymph; B: 6 weeks deaf, then artificial
perilymph). No pan-Trk-immunostained processes extended out of the
habenula perforata in tissues from deafened control animals (A and B; see
arrows). BDNF/FGF1 treatment resulted in one or more pan-Trk-im-
munostained processes. Pan-Trk-immunolabeled processes can be seen
extending through the habenula perforata (see arrows) and into the scar
region (see asterisks) in animals that received BDNF/FGF1 treatment 4
days after deafening (C) and in animals whose treatment was delayed
longer (D: 6 weeks postdeafening).
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RESULTS
SGC Peripheral Processes
Pan-Trk Selectively Labels Afferent Neurons.
The appearance of pan-Trk immunoperoxidase labeling
of a surface preparation is shown in Figure 1A. The
labeling is of afferent processes and terminals at the bases
of inner hair cells in the second turn of the cochlea from
a normal hearing guinea pig. Coimmunofluorescent
labeling for pan-Trk and the efferent-specific marker syn-
aptophysin shows that pan-Trk labeling of afferents
(green) is distinct from synaptophysin labeling of effer-
ents, in red (Fig. 1B), with perhaps a little portion of
‘‘yellowish’’ label from the overlap where efferents make
synaptic contact with afferents.
Pan-Trk-Positive Fiber Count. Pan-Trk-im-
munostained processes extending out of the habenula per-
forata were relatively rare in deafened control animals
receiving AP infusion, and when observed they never
extended very far past the habenula. One or more pan-
Trk-immunostained processes were found in almost all
BDNF/FGF1-treated animals (see Fig. 2). Processes in
animals treated with NTFs extended for variable distances
into the scar region of lost hair cells. Tissues from animals
that received BDNF/FGF1 after the shortest period of
deafness (4 days) generally contained more labeled fibers
than did those receiving delayed treatment (i.e., treatment
initiated after 3 or 6 weeks of deafness; see Fig. 3); how-
ever, the fibers in the delayed-treatment animals often had
the longest regrowth in the scar regions.
The increase in pan-Trk-positive SGC peripheral
processes (fibers) in both the 4-day- (immediate) and
delayed-treatment groups (i.e., Fig. 3) was statistically
significant. Two-way ANOVA revealed a statistically
significant (P  0.001) increase in peripheral processes in
the NTF-treated group compared to its AP control (F ¼
73.835, df ¼ 1,213; P < 0.001). An overall effect of
treatment delay was also observed (F ¼ 17.564, df ¼
2,213; P < 0.001), with greater numbers of fibers
observed after shorter delays. Pairwise comparisons, con-
ducted using the Tukey test, revealed that NTF treat-
ment reliably increased the number of fibers observed
over AP control material regardless of treatment delay
(all P < 0.005). There was a reliable interaction between
treatment and treatment delay (F ¼ 3.582, df ¼ 2,213; P
< 0.05). Pairwise comparisons revealed that animals in
the deafened control group, treated with AP, showed an
immediate and substantial decrease in pan-Trk-immuno-
labeled fiber count (4 days vs. 3 weeks, P < 0.05), with
no further loss associated with a 6-week delay (3 weeks
vs. 6 weeks, P > 0.05). However, with NTF treatment,
the number of fibers decreased from 4 days to 3 weeks
to 6 weeks (all P < 0.05).
Fig. 3. Treatment with a combination of NTFs (BDNF þ FGF1)
increased pan-Trk-positive spiral ganglion peripheral process (fiber)
count relative to the artificial perilymph (AP) control, even with
delayed treatment (all data are means 6 SEs). Pan-Trk-positive fiber
count did not vary with cochlear position; therefore, data from across
the cochlea were collapsed. *Statistically significant differences of
AP–NTF comparisons within each time point (all P < 0.005). An
overall effect-of-treatment delay was also observed, with a greater
number of fibers counted after shorter delays. Animals in the control
group, treated with AP, showed an immediate and substantial
decrease in fiber count (4 days vs. 3 weeks, P < 0.05), with no fur-
ther loss associated with a 6-week delay (3 weeks vs. 6 weeks, P >
0.05). With NTF treatment, the number of fibers decreased from 4
days to 3 weeks to 6 weeks (all P < 0.05).
Fig. 4. Representative paramodiolar plastic sections from four condi-
tions (groups) with profiles through Rosenthal’s canal and the organ
of Corti from first (basal) turn. Complete loss of hair cells occurred
in all four conditions, with scar tissue replacing the lost hair cells (see
solid black arrows), consistent with all groups being deafened in an
equivalent fashion prior to differential treatments. There was variabil-
ity in the number of remaining spiral ganglion cells among the four
treatment conditions. In deafened but untreated control animals (A: 4
days deaf, then artificial perilymph; B: 6 weeks deaf, then artificial
perilymph), the number of spiral ganglion cells per profile was greatly
reduced. The spiral ganglion cells evident in these tissues also
appeared smaller (see white arrows, A and B). In place of the missing
cells, significant vacuole formation was evident (see asterisks, A and
B). Treatment with neurotrophic factors increased spiral ganglion cell
survival, resulting in more spiral ganglion cells remaining in the pro-
files through Rosenthal’s canal. The spiral ganglion cells increased in
number and appeared larger in animals treated with BDNF/FGF1 4
days (C) and 6 weeks (D) following deafening.
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Cell Density of Spiral Ganglion Cells
Representative images of spiral ganglion cells are
shown in Figure 4. Treatment with a combination of
NTFs (BDNF þ FGF1) increased spiral ganglion cell den-
sity relative to AP control, even with delayed treatment
(see Fig. 5). Generally, the SGCs in cochleas with greater
survival also had a better appearance; they were larger,
rounder, without vacuolization, and with surrounding
myelin closely associated. Two-way ANOVA revealed a
statistically significant (P  0.001) enhancement of SGC
density in the NTF-treated group compared to its AP
control (F ¼ 404.669, df ¼ 1,216; P < 0.001). An overall
effect of treatment delay was also observed (F ¼ 61.491, df
¼ 2,216; P < 0.001), with greater density of fibers
observed after shorter delays. Pairwise comparisons, con-
ducted using the Tukey test, revealed that NTF treatment
reliably increased SGC density regardless of treatment
delay (all P < 0.001). There was a reliable interaction
between treatment and treatment delay (F ¼ 32.070, df ¼
2,216; P < 0.001). Moreover, pairwise comparisons
revealed that animals in the deafened control group,
treated with AP, showed an immediate and substantial
decrease in SGC density (4 days vs. 3 weeks, P < 0.05),
with no further loss associated with a 6-week delay (3
weeks vs. 6 weeks, P > 0.05). With NTF treatment, SGC
density did not decrease as treatment delay increased from
4 days to 3 weeks (P > 0.05); however, a decrease in SGC
density observed with further delay (3 weeks vs. 6 weeks)
in the NTF treatment groups was statistically reliable (P <
0.001). Additional comparisons revealed that increased
SGC density in 4-day- or 3-week-delayed NTF groups
compared with SGC density in untreated normal ears was
statistically reliable (all P < 0.01); decreased SGC density
in the AP groups and the 6-week-delayed NTF group
compared with SGC density in untreated normal ears was
also reliable (all P < 0.01).
DISCUSSION
Enhancement of SGC Processes, Even with
Delayed Treatment
BDNF and FGF1 reliably enhanced the number of
SGC peripheral processes, with significantly greater
counts of pan-Trk-positive processes emerging from the
habenula perforata when treatment was initiated 4 days,
3 weeks, or 6 weeks postdeafening. Pan-Trk labeling
was selective for AN processes, distinguishing AN proc-
esses from olivocochlear efferent fibers, which were not
labeled by pan-Trk (i.e., Fig. 1B). We found the greatest
number of pan-Trk-positive fibers with treatment
delayed only 4 days following deafness. With 3-week-
delayed treatment there was still a large increase, fivefold
over the labeling seen in the AP control animals. There
was a twofold increase over AP control levels in the ani-
mals with 6-week-delayed treatment with BDNF and
FGF1, but the total number was greatly reduced from
the 4-day and 3-week delays. This may suggest that at 6
weeks the deafferented SGCs had reduced responsiveness
to the NTFs. Alternatively, the reduced number of
regrown neurites may reflect that the NTFs have fewer
surviving SGCs to affect. Taken together, the combina-
tion of BDNF þ FGF1 was effective, even when deaf-
ness-induced degeneration had reduced the normal SGC
population by more than 40% after 6 weeks of deafness.
These results have significant clinical implications, sug-
gesting that even with delayed intervention, NTFs deliv-
ered at the time of implant will preserve SGCs in the
cochlea and initiate regrowth of peripheral processes.
Maintenance Versus Regrowth
A small number of pan-Trk-immunolabeled SGC
fibers were present in many control animals in which
AP delivery was initiated 4 days postdeafening and
assessment was 40 days following deafening. This sug-
gests that a small percentage of SGC peripheral processes
have a slower rate of degeneration, just as SGCs degen-
erate at different rates. It is possible that some small por-
tion of the increased number of pan-Trk-immunolabeled
fibers seen with BDNF and FGF1 treatment could reflect
maintenance of remaining peripheral processes, not just
induced regrowth. There were few pan-Trk-immunola-
beled fibers in the control group with longer delays and
assessment at longer times after deafness. This suggests
Fig. 5. Treatment with a combination of NTFs (BDNF þ FGF1)
increased spiral ganglion cell (SGC) density relative to artificial peril-
ymph (AP) control, even with delayed treatment (all data are means
6 SEs). SGC density did not vary with cochlear position; therefore,
data from across the cochlea were collapsed. *Statistically significant
differences of AP–NTF comparisons within each time point (all P <
0.001). An overall effect-of-treatment delay was also observed, with
greater density of fibers observed after shorter delays. Animals in the
control group, treated with AP, showed an early decrease in SGC
density (4 days vs. 3 weeks, P < 0.05), with no further loss associated
with a 6-week delay (3 weeks vs. 6 weeks, P > 0.05). With NTF
treatment, SGC density decreased later (4 days vs. 3 weeks, P >
0.05; 3 weeks vs. 6 weeks, P < 0.001). SGC density in all AP and
NTF groups reliably differed from normative data from 8 normal-
hearing untreated animals drawn from an existing laboratory database
(mean, dashed line; SE, dotted lines). Relative to that of normal-
hearing animals, SGC density was increased in the 4-day- and 3-
week-delayed NTF groups and was decreased in the AP groups and
the 6-week-delayed NTF group (all P < 0.01).
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that peripheral processes no longer remain at these later
times and that increases predominantly reflect regrowth.
Delayed NTF Treatment and SGC Survival
The current SGC density data indicate that BDNF/
FGF1 treatment is as efficacious as BDNF/CNTFAX1 is
in preventing deafferentation-induced cell death. With a
2-week delay in treatment, both BDNF/CNTFAX1
(Yamagata et al., 2004) and BDNF/FGF1 treatments
enhanced SGC density by approximately 3:1. Even with
a 6-week delay in treatment, both BDNF/CNTFAX1
(Yamagata et al., 2004) and BDNF/FGF1 treatments
enhanced SGC density by approximately 2:1. Although
in this study we found greater SGC density after BDNF/
FGF treatment (11–12 cells/10,000 lm2) than after
BDNF/CNTF treatment (3–5 cells/10,000 lm2), SGC
density ratios for treated and untreated ears were similar,
as we observed greater cell density in control tissues rela-
tive to that reported by Yamagata et al. (2004). Differen-
ces in cell survival in deafened control animals found in
different investigations may reflect variation in the spe-
cific deafening protocol used (kanamycin/ethacrynic acid
or 10% neomycin injected into the middle ear). As illus-
trated in Figure 4, ‘‘surviving’’ SGCs in AP-treated con-
trol animals were not completely normal in appearance,
with some vacuolization, mitochondrial clumping, and
nuclear displacement. These cells might not then be ca-
pable of normal function. Taken together, the data
clearly demonstrate that although earlier treatment is
superior, reliable increases in measures of cell survival can
be observed even after a 6-week delay in treatment with
either BDNF/FGF1 or BDNF/CNTFAX1.
Increase in SGCs: Could There Be Endogenous
Populations of Precursor Cells?
In normal ears, average SGC density was 9.49 (6 0.6)
cells/10,000 lm2 (see dashed line in Fig. 5). However,
interestingly, in tissues from animals treated 4 days post-
deafening, mean SGC density was 11.8 (6 0.4) cells/
10,000 lm2. Similarly, in tissues from animals treated 3
weeks postdeafening, mean SGC density was 10.9 (6 0.8)
cells/10,000 lm2. The observed increased SGC density in
NTF-treated ears was statistically significant (P < 0.01).
One possible explanation for this increased SGC density is
that NTFs induced conversion of endogenous precursor or
stem cells into neurons and thus greater cell density than
that seen in tissues from normal animals. Indeed, there is
now evidence that human and guinea pig AN both have
the potential for self-renewal. Rask-Andersen et al. (2005)
demonstrated that progenitor/stem cells removed to cul-
ture from human modiolus divide, multiply, and form neu-
rospheres that then spin off individual cells that differentiate
into mature neurons (expressing TrkB and TrkC receptors)
or glial cells. They report that this process and the neurite
growth observed in mature neurons are enhanced by
NTFs. Such pluripotential cells have also been generated
from whole cochlea and vestibular tissue from mice (Li
et al., 2003) . An alternative interpretation is that deafness
induces transdifferentiation of glia into new SGCs and that
NTFs applied at or near the time of trauma cause dediffer-
entiation of SGCs to an earlier developmental state where
they are capable of reentering the cell cycle, dividing, and
differentiating into new (more) SGCs. The evidence sup-
porting this dedifferentiation hypothesis includes the obser-
vation that spiral ganglion neurons evaluated after amino-
glycoside treatment resemble gestational neurons (Dodson,
1997; Dodson and Mohuiddin, 2000). These may then
provide a future mechanism for AN replacement, along
with application of exogenous stem cells (Ito et al., 2001;
Iguchi et al., 2003; Tamura et al., 2004; Hu et al., 2005;).
The potential for clinical impact of increasing AN survival/
regrowth is clearly increased when these results are consid-
ered in combination with the demonstration of hair cell
regeneration in guinea pigs (Izumikawa et al., 2005).
Combinations of Treatments
The benefits of combined treatment with NTFs and
electrical stimulation were shown by Kanzaki et al. (2002),
who induced expression of GDNF in the cochlea using vi-
ral vectors (delivered 5 days postdeafening) and initiated
electrical stimulation 8 days postdeafening. Ears treated
with GDNF (approximately 9 cells/10,000 lm2) had sig-
nificantly greater SGC density than did electrically stimu-
lated ears (approximately 7.5 cells/10,000 lm2); ears
treated with a combination of GDNF þ electrical stimula-
tion (approximately 10.5 cells/10,000 lm2) had signifi-
cantly greater SGC density than that of ears treated with ei-
ther GDNF or electrical stimulation alone. That the factors
were additive indicates that GDNF and electrical stimula-
tion exert their protective effects through separate bio-
chemical pathways; however, because the concentration
of GDNF delivered cannot be specified or demonstrated
to be optimal, mechanistic interpretation of these findings
must be made cautiously. Because the combination of
BDNF þ FGF1 described in this study (approximately 11
cells/10,000 lm2) was more efficacious in supporting
SGC survival than was GDNF in the studies of Kanzaki
et al. (2002) and others (627–877 cells/10,000 mm2; Yli-
koski et al., 1998), these results suggest BDNF þ FGF1 þ
electrical stimulation may better enhance SGC survival
than other NTFþ electrical stimulation combinations.
As reviewed by Gillespie et al. (2003), BDNF
treatment can increase nitric oxide synthase (NOS) and
nitric oxide (NO) production. Combination therapy that
includes NTFs and either NOS inhibitors or free-radical
scavengers (that bind to NO) might therefore be advan-
tageous. For example, some interventions use antioxi-
dants to reduce ROS associated with neurotrophin de-
privation (see Satoh et al., 1999; Yamagata et al., 1999).
Similar interventions are likely to be successful in the
auditory system: whereas application of BDNF decreased
cisplatin-induced ROS and improved survival, with-
drawal of BDNF increased ROS in auditory neurons
(Gabaizadeh et al., 1997). Like NTFs, free-radical scav-
engers can be delivered directly into the cochlea, using
viral vectors, for example Kawamoto et al., 2004. These
1966 Miller et al.
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agents can also be delivered locally in the cochlea, and
both systemic and local delivery of a combination of
vitamin C (ascorbic acid) and vitamin E (trolox) have
been shown to effectively increase SGC density and pre-
serve auditory function (assessed as eABR threshold) fol-
lowing deafening via local intracochlear injection of the
aminoglycoside neomycin (Maruyama et al., 2007). As
described above for other NTF combinations, delivering
both GDNF and vitamins C and E protected auditory
thresholds significantly better than did GDNF alone
(Maruyama et al., 2003). Therapies that include antioxi-
dant agents may have the additional benefit of acting to
preserve not only neural populations, but also hair cells
(for a review, see Le Prell et al., 2007b).
Clinical Trials for Translation to Humans
Clinical trials with neurotrophic factors have in the
past been challenging because of the short in vivo half-
life of NTFs, as well as poor pharmacokinetics, proteo-
lytic degradation, and inability of these large polypep-
tides to cross the blood–brain barrier when delivered sys-
temically (for a review, see Saragovi and Gehring, 2000).
However, recent improvements in drug delivery techni-
ques, including, for example, gene therapy, stem-cell
therapy, microencapsulation of neurotrophins (or geneti-
cally engineered cells that secret neurotrophins), and
design of small-molecule neurotrophin mimetics, all pro-
vide potential solutions (for a review, see Saragovi and
Gehring, 2000). Moreover, in the case of the impaired
inner ear, neurotrophic agents can be delivered directly
into the cochlea during implant procedures, thus reduc-
ing potential blood–brain barrier issues and attaining rel-
atively high concentrations with restricted systemic side
effects. Because many nutritional supplements (i.e., vita-
mins A, C, and E) are potent free-radical scavengers that
can be consumed orally with no adverse side effects
when taken at recommended doses, the potential for
combination therapeutics in humans is clear.
CONCLUSIONS
This study is the first in vivo demonstration that
SGCs are capable of regrowing their peripheral processes
following degeneration. Moreover, regrowth is possible
in a population that has sufficiently advanced toward cell
death that more than 40% of the SGCs have been
destroyed. If the NTF intervention initiates neurite
growth in endogenous neurons, it may be that such an
intervention may also be used to stimulate neurite
growth in exogenous (stem) cell implants, enabling inte-
gration of implants into the central pathways. A
regrowth of excitable processes in the implanted ear may
enhance integration of an implant with the nervous sys-
tem, reducing battery requirements, increasing frequency
separation, and allowing more channels of information
and superior benefits to patients receiving cochlear
implants. These findings provide a basis for future studies
that will examine if the regrowth can be directed toward
specific sites on a prosthesis.
As the criteria for implanting human patients with
cochlear prostheses are expanded (National Institutes of
Health, 1995), patients with greater residual hearing (and
thus greater residual populations of apical hair cells and
neurons) are receiving intracochlear devices. By combin-
ing implant procedures that minimize surgical trauma (to
retain these residual populations of apical hair cells and
neurons; e.g., Lehnhardt, 1993; Cohen, 1997) and deliv-
ering NTFs to stimulate neural proliferation toward the
prosthesis, cochlear implant function and the corre-
sponding ‘‘acoustic’’ sensation are likely to significantly
improve. Consistent with this prediction, Gantz et al.
implanted shorter (10-mm) intracochlear electrode arrays
that preserve intact low-frequency hearing. Electrical
stimulation of the base of the cochlea combined with
acoustic stimulation of the intact apical cochlea (via
hearing aid use) enhanced perceptual experience for
cochlear implant users (Gantz et al., 2000; 2004; Tyler
et al., 2000; Gantz and Turner 2003; Turner et al.,
2004). Similar results were described in a case study by
Skarzynski et al. (2003). Recent data from Le Prell et al.
(2006) document the potential for electrical stimulation
of intact/remaining hair cell populations to produce
tonelike auditory sensations with electrical stimulation of
the cochlea. With the potential that one day we will be
able to induce hair cell regeneration in humans, such as
that which has now been done in guinea pigs (Izumi-
kawa et al., 2005), the potential for interventions that
increase neural survival are ever more important. The
addition of free-radical scavengers to the treatment regi-
men is likely to further improve clinical outcome given
the positive effects on both hair cell and neural survival
(Le Prell et al., 2007a; Maruyama et al., 2007). Taken
together, the ability to preserve and induce regrowth of
AN fibers is a key clinical outcome that will be increas-
ingly important as mechanisms of hair cell preservation
and regeneration continue to improve.
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